<DOC>
	<DOCNO>NCT01074463</DOCNO>
	<brief_summary>The object study compare relative bioavailability ( rate extent absorption ) Pramipexole Dihydrochloride Tablets 0.25 mg Barr Laboratories , Inc. Mirapex® Tablets 0.25 mg distribute Boehringer Ingelheim Pharmaceuticals , Inc. follow single oral dose healthy adult non-fasting condition .</brief_summary>
	<brief_title>Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA Bioequivalence Statistical Methods</detailed_description>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>All volunteer select study healthy men woman 18 45 year age , inclusive . The weight range exceed + 20 % height body frame per `` Desirable Weights Adults 1983 Metropolitan Height Weight Table '' Each volunteer complete screening process within 28 day prior Period 1 dosing . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . If female : child bear potential practicing acceptable method birth control duration study judge investigator ( ) , postmenopausal least 1 year , surgically sterile . Volunteers recent history drug alcohol addiction abuse . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Volunteers demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . Volunteers demonstrate positive drug abuse screen screen study . Female volunteer demonstrate positive pregnancy screen . Female volunteer currently breastfeed . Volunteers history allergic response ( ) pramipexole relate drug . Volunteers history clinically significant allergy include drug allergy . Volunteers clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Volunteers currently use tobacco product . Volunteers take drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . Volunteers report donate great 150 mL blood within 28 day prior Period I dose . All subject advise donate blood 4 week complete study . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma 4 week complete study . Volunteers report receive investigational drug within 28 day prior Period I dose . Volunteer report take systemic prescription medication 14 day prior Period I dose . Diltiazem ( Cardizem® ) , triamterene ( Dyrenium® ) , verapamil ( Calan® , CoveraHS® ) , quinidine , quinine prohibit throughout entire study . Volunteers use OTC medication 7 day prior dose include vitamin , cough cold preparation . Cimetidine ( Tagamet® ) , ranitidine ( Zantac® ) , probenecid ( ProBionate® ) , OTC antihistamine product ( diphenhydramine , chlorpheniramine ) absolutely prohibit throughout entire study . Volunteers consume food contain poppy seed 48 hour dose period . Volunteers consume grapefruit relate product 14 day prior Period I dose . Female volunteer report use oral contraceptive injectable contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>